Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Prescribing antidepressants according to biological markers may improve response rates. | Drug Discovery And Development ...
Woman's World on MSN
Could vagus nerve stimulation help manage major depressive disorder?
Vagus nerve stimulation may help manage major depressive disorder, according to new research and expert interviews. The ...
A single dose of the LSD-based therapy DT120 produced rapid antidepressant effects that remained significant through 12 weeks in a pivotal phase 3 trial of major depressive disorder.
Major depressive disorder (MDD) is a psychiatric condition characterized by persistent feelings of sadness, a loss of ...
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid ...
Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD). Jay Weaver, PharmD, MPH: When we’ve looked at health equity and disparities in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results